Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzyme gene

BMC Med Genet. 2011 Nov 22:12:151. doi: 10.1186/1471-2350-12-151.

Abstract

Background: Insulin-degrading enzyme (IDE) is the ubiquitously expressed enzyme responsible for insulin and amyloid beta (Aβ) degradation. IDE gene is located on chromosome region 10q23-q25 and exhibits a well-replicated peak of linkage with Type 2 diabetes mellitus (T2DM). Several genetic association studies examined IDE gene as a susceptibility gene for Alzheimer's disease (AD), however with controversial results.

Methods: We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, rs2251101 and IDE9, rs1887922) with AD, Aβ42 plasma level and T2DM risk in the longitudinal Vienna Transdanube Aging (VITA) study cohort.

Results: The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Aβ42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic variant IDE9.

Conclusions: Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3' untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant endophenotype with disorder-specific effects on AD and T2DM susceptibility.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions
  • Alzheimer Disease / genetics
  • Amyloid beta-Peptides / blood
  • Cohort Studies
  • Diabetes Mellitus, Type 2 / genetics
  • Genetic Association Studies
  • Genotype
  • Haplotypes
  • Humans
  • Insulysin / genetics*
  • Longitudinal Studies
  • Peptide Fragments / blood
  • Polymorphism, Single Nucleotide*
  • Promoter Regions, Genetic
  • Risk

Substances

  • 3' Untranslated Regions
  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • Insulysin